{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T00:16:31Z","timestamp":1792800991543,"version":"4.5.0"},"reference-count":47,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,1,24]],"date-time":"2026-01-24T00:00:00Z","timestamp":1769212800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,2,17]],"date-time":"2026-02-17T00:00:00Z","timestamp":1771286400000},"content-version":"vor","delay-in-days":24,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82302007"],"award-info":[{"award-number":["82302007"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Young Talent Fund of Sichuan Provincial People\u2019s Hospital","award":["Young Talent Fund of Sichuan Provincial People\u2019s Hospital"],"award-info":[{"award-number":["Young Talent Fund of Sichuan Provincial People\u2019s Hospital"]}],"id":[{"id":"https:\/\/ror.org\/03wwr4r78","id-type":"ROR","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Orphanet J Rare Dis"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Inborn errors of immunity (IEI), though individually rare, collectively represent a significant disease burden. From 1980 to 2024, classified IEI disorders expanded from dozens to 559 entities, reflecting advances ranging from immunoglobulin replacement to gene therapy.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This bibliometric analysis\u2014a comprehensive mapping of the global IEI landscape\u2014analyzed 7,455 publications (1991\u20132025) from Web of Science Core Collection using Bibliometrix, VOSviewer, and CiteSpace.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Key findings: (1) Annual publication growth: 10.27% (H-index\u2009=\u2009173); (2) US dominance: 36.3% publications, 115,221 citations, and TLS\u2009=\u2009105,825; (3) Research priorities: Immunodeficiency mechanisms, clinical diagnostics, and key diseases (SCID, CVID, APDS); (4) Therapeutic frontiers: HSCT, gene therapy, targeted signaling inhibitors. (5) Critical gaps: Newborn screening implementation, quality-of-life metrics.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>This study provide a comprehensive, multidimensional visualization of the IEI research landscape over 35 years. Although the field maintains a high H-index and broad scope, the pace of research growth appears to have stabilized in the past five years. It is important to note that the observed flattening in total citation counts during this period may be influenced by citation windows and pandemic-related confounding, and should not be interpreted as definitive evidence of field maturity or stagnation. Nonetheless, this observed pattern highlights that that sustaining historical growth rates may require transformative technological advances\u2014particularly in gene editing\u2014to catalyze the next wave of progress in IEI research.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s13023-025-04191-4","type":"journal-article","created":{"date-parts":[[2026,1,24]],"date-time":"2026-01-24T14:35:15Z","timestamp":1769265315000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Global research landscape of inborn errors of immunity: a bibliometric analysis (1991\u20132025)"],"prefix":"10.1186","volume":"21","author":[{"given":"Qibin","family":"Wu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jingxian","family":"Gao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yinglin","family":"Yuan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongji","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3378-2056","authenticated-orcid":false,"given":"Qiang","family":"Fu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,1,24]]},"reference":[{"issue":"1","key":"4191_CR1","doi-asserted-by":"publisher","first-page":"e20250003","DOI":"10.70962\/jhi.20250003","volume":"1","author":"M Cecilia Poli","year":"2025","unstructured":"Cecilia Poli M, et al. Human inborn errors of immunity: 2024 update on the classification from the international union of immunological societies expert committee. J Hum Immun. 2025;1(1):e20250003.","journal-title":"J Hum Immun"},{"issue":"1","key":"4191_CR2","doi-asserted-by":"publisher","first-page":"e20250002","DOI":"10.70962\/jhi.20250002","volume":"1","author":"A Ahmed","year":"2025","unstructured":"Ahmed A, Bousfiha, et al. The 2024 update of IUIS phenotypic classification of human inborn errors of immunity. J Hum Immun. 2025;1(1):e20250002.","journal-title":"J Hum Immun"},{"key":"4191_CR3","doi-asserted-by":"crossref","unstructured":"Picard C et al. International union of immunological societies: 2017 primary immunodeficiency diseases committee report on inborn errors of immunity. J Clin Immunol, 2018. 38(1).","DOI":"10.1007\/s10875-017-0464-9"},{"issue":"6","key":"4191_CR4","doi-asserted-by":"publisher","first-page":"722","DOI":"10.1542\/peds.9.6.722","volume":"9","author":"OC Bruton","year":"1952","unstructured":"Bruton OC. Agammaglobulinemia Pediatr. 1952;9(6):722\u20138.","journal-title":"Agammaglobulinemia Pediatr"},{"key":"4191_CR5","doi-asserted-by":"crossref","unstructured":"Notarangelo LD et al. Human inborn errors of immunity: an expanding universe. Sci Immunol, 2020. 5(49).","DOI":"10.1126\/sciimmunol.abb1662"},{"issue":"7583","key":"4191_CR6","doi-asserted-by":"publisher","first-page":"1366","DOI":"10.1016\/S0140-6736(68)92673-1","volume":"2","author":"RA Gatti","year":"1968","unstructured":"Gatti RA, et al. Immunological reconstitution of sex-linked lymphopenic immunological deficiency. Lancet (London England). 1968;2(7583):1366\u20139.","journal-title":"Lancet (London England)"},{"issue":"25","key":"4191_CR7","doi-asserted-by":"publisher","first-page":"2718","DOI":"10.1182\/blood-2017-05-781849","volume":"130","author":"J Heimall","year":"2017","unstructured":"Heimall J, et al. Immune reconstitution and survival of 100 SCID patients post-hematopoietic cell transplant: a PIDTC natural history study. Blood. 2017;130(25):2718\u201327.","journal-title":"Blood"},{"issue":"3","key":"4191_CR8","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1016\/j.bbmt.2016.12.619","volume":"23","author":"J Heimall","year":"2017","unstructured":"Heimall J, et al. Current knowledge and priorities for future research in late effects after hematopoietic stem cell transplantation (HCT) for severe combined immunodeficiency patients: A consensus statement from the second pediatric blood and marrow transplant consortium international conference on late effects after pediatric HCT. Biology Blood Marrow Transplantation: J Am Soc Blood Marrow Transplantation. 2017;23(3):379\u201387.","journal-title":"Biology Blood Marrow Transplantation: J Am Soc Blood Marrow Transplantation"},{"key":"4191_CR9","doi-asserted-by":"crossref","unstructured":"Wijeyesinghe S, Chinen J. Gene therapy for inborn errors of immunity: current clinical progress. Annals of Allergy, Asthma & Immunology: Official Publication of the American College of Allergy, Asthma, & Immunology, 2025;134(6):630\u2013638.","DOI":"10.1016\/j.anai.2025.02.026"},{"issue":"10","key":"4191_CR10","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1056\/NEJM198703053161005","volume":"316","author":"MS Hershfield","year":"1987","unstructured":"Hershfield MS, et al. Treatment of adenosine deaminase deficiency with polyethylene glycol-modified adenosine deaminase. N Engl J Med. 1987;316(10):589\u201396.","journal-title":"N Engl J Med"},{"issue":"5","key":"4191_CR11","doi-asserted-by":"publisher","first-page":"1665","DOI":"10.1016\/j.jaci.2018.07.020","volume":"142","author":"LR Forbes","year":"2018","unstructured":"Forbes LR, et al. Jakinibs for the treatment of immune dysregulation in patients with gain-of-function signal transducer and activator of transcription 1 (STAT1) or STAT3 mutations. J Allergy Clin Immunol. 2018;142(5):1665\u20139.","journal-title":"J Allergy Clin Immunol"},{"issue":"21","key":"4191_CR12","doi-asserted-by":"publisher","first-page":"2307","DOI":"10.1182\/blood-2017-08-801191","volume":"130","author":"VK Rao","year":"2017","unstructured":"Rao VK, et al. Effective activated PI3K\u03b4 syndrome-targeted therapy with the PI3K\u03b4 inhibitor Leniolisib. Blood. 2017;130(21):2307\u201316.","journal-title":"Blood"},{"issue":"5","key":"4191_CR13","doi-asserted-by":"publisher","first-page":"1139","DOI":"10.1016\/j.jaip.2024.01.019","volume":"12","author":"ACA Mudde","year":"2024","unstructured":"Mudde ACA, et al. What a clinician needs to know about genome editing: status and opportunities for inborn errors of immunity. J Allergy Clin Immunol Pract. 2024;12(5):1139\u201349.","journal-title":"J Allergy Clin Immunol Pract"},{"key":"4191_CR14","doi-asserted-by":"publisher","first-page":"1051","DOI":"10.1182\/blood-2024-202543","volume":"144","author":"K Masiuk","year":"2024","unstructured":"Masiuk K, et al. Ex vivo lentiviral hematopoietic stem cell (HSC) gene therapy May represent a curative therapy for the Life-Threatening inborn error of immunity severe combined immunodeficiency due to adenosine deaminase (ADA) deficiency (ADA-SCID). Blood. 2024;144:1051.","journal-title":"Blood"},{"issue":"1","key":"4191_CR15","doi-asserted-by":"publisher","first-page":"1315","DOI":"10.1038\/s41467-022-28762-2","volume":"13","author":"F Tucci","year":"2022","unstructured":"Tucci F, et al. A systematic review and meta-analysis of gene therapy with hematopoietic stem and progenitor cells for Monogenic disorders. Nat Commun. 2022;13(1):1315.","journal-title":"Nat Commun"},{"issue":"12","key":"4191_CR16","first-page":"3392","volume":"30","author":"K O\u2019Leary","year":"2024","unstructured":"O\u2019Leary K. Prime time for gene editing. Nat Med. 2024;30(12):3392\u20133.","journal-title":"Nat Med"},{"issue":"3","key":"4191_CR17","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1056\/NEJMoa2031054","volume":"384","author":"H Frangoul","year":"2021","unstructured":"Frangoul H, et al. CRISPR-Cas9 gene editing for sickle cell disease and \u03b2-Thalassemia. N Engl J Med. 2021;384(3):252\u201360.","journal-title":"N Engl J Med"},{"issue":"18","key":"4191_CR18","doi-asserted-by":"publisher","first-page":"1649","DOI":"10.1056\/NEJMoa2309676","volume":"390","author":"H Frangoul","year":"2024","unstructured":"Frangoul H, et al. Exagamglogene autotemcel for severe sickle cell disease. N Engl J Med. 2024;390(18):1649\u201362.","journal-title":"N Engl J Med"},{"issue":"22","key":"4191_CR19","doi-asserted-by":"publisher","first-page":"2235","DOI":"10.1056\/NEJMoa2504747","volume":"392","author":"K Musunuru","year":"2025","unstructured":"Musunuru K, et al. Patient-Specific in vivo gene editing to treat a rare genetic disease. N Engl J Med. 2025;392(22):2235\u201343.","journal-title":"N Engl J Med"},{"key":"4191_CR20","doi-asserted-by":"publisher","first-page":"1371124","DOI":"10.3389\/fimmu.2024.1371124","volume":"15","author":"N Xiao","year":"2024","unstructured":"Xiao N, et al. Health-related quality of life in patients with inborn errors of immunity: a bibliometric analysis. Front Immunol. 2024;15:1371124.","journal-title":"Front Immunol"},{"issue":"13","key":"4191_CR21","doi-asserted-by":"publisher","first-page":"e33295","DOI":"10.1097\/MD.0000000000033295","volume":"102","author":"S Hu","year":"2023","unstructured":"Hu S, et al. The research on the treatment of primary immunodeficiency diseases by hematopoietic stem cell transplantation: A bibliometric analysis from 2013 to 2022. Medicine. 2023;102(13):e33295.","journal-title":"Medicine"},{"issue":"50","key":"4191_CR22","doi-asserted-by":"publisher","first-page":"e32347","DOI":"10.1097\/MD.0000000000032347","volume":"101","author":"S Liu","year":"2022","unstructured":"Liu S, et al. Frontier and hotspot evolution in Wiskott-Aldrich syndrome: A bibliometric analysis from 2001 to 2021. Medicine. 2022;101(50):e32347.","journal-title":"Medicine"},{"key":"4191_CR23","first-page":"6204","volume":"10","author":"F Bakri","year":"2017","unstructured":"Bakri F, Adwan M, El-Shanti H. Citation classics in chronic granulomatous disease: A bibliometric analysis. Int J Clin Exp Med. 2017;10:6204\u201320.","journal-title":"Int J Clin Exp Med"},{"issue":"6","key":"4191_CR24","doi-asserted-by":"publisher","first-page":"1763","DOI":"10.1016\/j.jaip.2019.02.004","volume":"7","author":"MG Seidel","year":"2019","unstructured":"Seidel MG, et al. The European society for immunodeficiencies (ESID) registry working definitions for the clinical diagnosis of inborn errors of immunity. J Allergy Clin Immunol Pract. 2019;7(6):1763\u201370.","journal-title":"J Allergy Clin Immunol Pract"},{"issue":"9","key":"4191_CR25","doi-asserted-by":"publisher","first-page":"656","DOI":"10.1182\/blood.2019000929","volume":"135","author":"H Abolhassani","year":"2020","unstructured":"Abolhassani H, Hammarstr\u00f6m L, Cunningham-Rundles C. Current genetic landscape in common variable immune deficiency. Blood. 2020;135(9):656\u201367.","journal-title":"Blood"},{"issue":"2","key":"4191_CR26","doi-asserted-by":"publisher","first-page":"520","DOI":"10.1016\/j.jaci.2020.09.010","volume":"147","author":"I Meyts","year":"2021","unstructured":"Meyts I, et al. Coronavirus disease 2019 in patients with inborn errors of immunity: an international study. J Allergy Clin Immunol. 2021;147(2):520\u201331.","journal-title":"J Allergy Clin Immunol"},{"key":"4191_CR27","unstructured":"Zhang Q et al. Inborn errors of type I IFN immunity in patients with life-threatening COVID-19. Science (New York, N.Y.). 2020;370(6515):eabd4570."},{"key":"4191_CR28","unstructured":"Bastard P et al. Autoantibodies against type I IFNs in patients with life-threatening COVID-19. Science (New York, N.Y.). 2020;370(6515):eabd4585."},{"key":"4191_CR29","unstructured":"Thalhammer J et al. Initial presenting manifestations in 16,486 patients with inborn errors of immunity include infections and noninfectious manifestations. J Allergy Clin Immunol, 2021. 148(5)."},{"issue":"3","key":"4191_CR30","doi-asserted-by":"publisher","first-page":"740","DOI":"10.1016\/j.jaci.2024.12.1075","volume":"155","author":"H Ijspeert","year":"2025","unstructured":"Ijspeert H, et al. Update on inborn errors of immunity. J Allergy Clin Immunol. 2025;155(3):740\u201351.","journal-title":"J Allergy Clin Immunol"},{"issue":"1","key":"4191_CR31","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1007\/s10875-019-00737-x","volume":"40","author":"SG Tangye","year":"2020","unstructured":"Tangye SG, et al. Human inborn errors of immunity: 2019 update on the classification from the international union of immunological societies expert committee. J Clin Immunol. 2020;40(1):24\u201364.","journal-title":"J Clin Immunol"},{"issue":"1","key":"4191_CR32","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1007\/s10875-020-00758-x","volume":"40","author":"A Bousfiha","year":"2020","unstructured":"Bousfiha A, et al. Human inborn errors of immunity: 2019 update of the IUIS phenotypical classification. J Clin Immunol. 2020;40(1):66\u201381.","journal-title":"J Clin Immunol"},{"issue":"8","key":"4191_CR33","doi-asserted-by":"publisher","first-page":"696","DOI":"10.1007\/s10875-015-0201-1","volume":"35","author":"C Picard","year":"2015","unstructured":"Picard C, et al. Primary immunodeficiency diseases: an update on the classification from the international union of immunological societies expert committee for primary immunodeficiency 2015. J Clin Immunol. 2015;35(8):696\u2013726.","journal-title":"J Clin Immunol"},{"issue":"1","key":"4191_CR34","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1186\/s13223-022-00662-6","volume":"18","author":"J Quinn","year":"2022","unstructured":"Quinn J, et al. Growth in diagnosis and treatment of primary immunodeficiency within the global Jeffrey modell centers network. Allergy Asthma Clin Immunology: Official J Can Soc Allergy Clin Immunol. 2022;18(1):19.","journal-title":"Allergy Asthma Clin Immunology: Official J Can Soc Allergy Clin Immunol"},{"issue":"1","key":"4191_CR35","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1007\/s10875-024-01810-w","volume":"45","author":"S Fekrvand","year":"2024","unstructured":"Fekrvand S, et al. Cancer trends in inborn errors of immunity: A systematic review and Meta-Analysis. J Clin Immunol. 2024;45(1):34.","journal-title":"J Clin Immunol"},{"key":"4191_CR36","doi-asserted-by":"crossref","unstructured":"Neth O et al. Spanish consensus on the diagnosis and management of patients with activated PI3K delta syndrome (APDS). J Investigat Allergol Clin Immunol, 2025. 35(2).","DOI":"10.18176\/jiaci.1059"},{"issue":"3","key":"4191_CR37","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1007\/s12016-019-08738-9","volume":"59","author":"M Jamee","year":"2020","unstructured":"Jamee M, et al. Clinical, Immunological, and genetic features in patients with activated PI3K\u03b4 syndrome (APDS): a systematic review. Clin Rev Allergy Immunol. 2020;59(3):323\u201333.","journal-title":"Clin Rev Allergy Immunol"},{"issue":"1","key":"4191_CR38","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1186\/s13052-024-01662-5","volume":"50","author":"V Lougaris","year":"2024","unstructured":"Lougaris V, et al. Activated Phosphoinositde 3-kinase (PI3K\u03b4) syndrome: an Italian point of view on diagnosis and new advances in treatment. Ital J Pediatr. 2024;50(1):103.","journal-title":"Ital J Pediatr"},{"issue":"2","key":"4191_CR39","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1016\/j.jaci.2024.09.020","volume":"155","author":"S Samra","year":"2025","unstructured":"Samra S, et al. JAK-STAT signaling pathway, immunodeficiency, inflammation, immune dysregulation, and inborn errors of immunity. J Allergy Clin Immunol. 2025;155(2):357\u201367.","journal-title":"J Allergy Clin Immunol"},{"key":"4191_CR40","doi-asserted-by":"crossref","unstructured":"Fischer M et al. JAK inhibitor treatment for inborn errors of JAK\/STAT signaling: an ESID\/EBMT-IEWP retrospective study. J Allergy Clin Immunol, 2024. 153(1).","DOI":"10.1016\/j.jaci.2023.10.018"},{"issue":"10396","key":"4191_CR41","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1016\/S0140-6736(23)00731-6","volume":"402","author":"MS Thakar","year":"2023","unstructured":"Thakar MS, et al. Measuring the effect of newborn screening on survival after Haematopoietic cell transplantation for severe combined immunodeficiency: a 36-year longitudinal study from the primary immune deficiency treatment consortium. Lancet (London England). 2023;402(10396):129\u201340.","journal-title":"Lancet (London England)"},{"issue":"10396","key":"4191_CR42","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1016\/S0140-6736(23)00731-6","volume":"402","author":"MS Thakar","year":"2023","unstructured":"Thakar MS, et al. Measuring the effect of newborn screening on survival after Haematopoietic cell transplantation for severe combined immunodeficiency: a 36-year longitudinal study from the primary immune deficiency treatment consortium. Lancet. 2023;402(10396):129\u201340.","journal-title":"Lancet"},{"issue":"6","key":"4191_CR43","doi-asserted-by":"publisher","first-page":"630","DOI":"10.1016\/j.anai.2025.02.026","volume":"134","author":"S Wijeyesinghe","year":"2025","unstructured":"Wijeyesinghe S, Chinen J. Gene therapy for inborn errors of immunity: current clinical progress. Ann Allergy Asthma Immunol. 2025;134(6):630\u20138.","journal-title":"Ann Allergy Asthma Immunol"},{"key":"4191_CR44","doi-asserted-by":"publisher","first-page":"p1430678","DOI":"10.3389\/fimmu.2024.1430678","volume":"15","author":"S Van Coillie","year":"2024","unstructured":"Van Coillie S, et al. Charting a course for global progress in PIDs by 2030 - proceedings from the IPOPI global multi-stakeholders\u2019 summit (September 2023). Front Immunol. 2024;15:p1430678.","journal-title":"Front Immunol"},{"issue":"4","key":"4191_CR45","doi-asserted-by":"publisher","first-page":"959","DOI":"10.1016\/j.joi.2017.08.007","volume":"11","author":"M Aria","year":"2017","unstructured":"Aria M, Cuccurullo C. Bibliometrix: an r-tool for comprehensive science mapping analysis. J Informetrics J Informetrics. 2017;11(4):959\u201375.","journal-title":"J Informetrics J Informetrics"},{"issue":"2","key":"4191_CR46","doi-asserted-by":"publisher","first-page":"523","DOI":"10.1007\/s11192-009-0146-3","volume":"84","author":"NJ van Eck","year":"2010","unstructured":"van Eck NJ, Waltman L. Software survey: VOSviewer, a computer program for bibliometric mapping. Scientometrics. 2010;84(2):523\u201338.","journal-title":"Scientometrics"},{"issue":"3","key":"4191_CR47","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1002\/asi.20317","volume":"57","author":"C Chen","year":"2006","unstructured":"Chen C. Citespace ii: detecting and visualizing emerging trends and transient patterns in scientific literature. J Am Soc Inf Sci Technol. 2006;57(3):359\u201377.","journal-title":"J Am Soc Inf Sci Technol"}],"container-title":["Orphanet Journal of Rare Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13023-025-04191-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13023-025-04191-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13023-025-04191-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,17]],"date-time":"2026-02-17T11:56:14Z","timestamp":1771329374000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s13023-025-04191-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,24]]},"references-count":47,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["4191"],"URL":"https:\/\/doi.org\/10.1186\/s13023-025-04191-4","relation":{},"ISSN":["1750-1172"],"issn-type":[{"value":"1750-1172","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,24]]},"assertion":[{"value":"18 September 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 December 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 January 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"64"}}